Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial

In patients with ACS and relevant non-culprit coronary artery lesions, the addition of evolocumab to HIST for 12 weeks, compared to placebo, did not result in improvement of FFR or maxLCBI<sub>4mm</sub>. (ClinicalTrials.gov: NCT04141579).

Authors

Institutions

Publication Details

Journal
EuroIntervention
Published
2025-08-01
DOI
https://doi.org/10.4244/eij-d-24-01065
Citations
5
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
10.03
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial

Tim J.F. ten Cate, Aysun Cetinyurek‐Yavuz, Marleen van Wely, Alexander Ijsselmuiden et al.
5 citations
EuroIntervention
Lipoproteins and Cardiovascular Health
10.03
article

Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial

Tim J.F. ten Cate, Aysun Cetinyurek‐Yavuz, Marleen van Wely, Alexander Ijsselmuiden, Rohit M. Oemrawsingh, Aukelien C. Dimitriu‐Leen, Himanshu Rai, Robert‐Jan van Geuns, Peter Damman, Diederik F. van Wijk, Martijn Meuwissen, Clemens von Birgelen, Valeria Paradies, Frans B. Mensink, J. Los, Cyril Camaro, Lokien X. van Nunen, Pieter C. Smits, Jin M. Cheng, Robert A Byrne, Mohamed M Reda Abdelaziz Morsy, Niels van Royen, Dirk J van Wijk
article en
5 citations

Abstract

In patients with ACS and relevant non-culprit coronary artery lesions, the addition of evolocumab to HIST for 12 weeks, compared to placebo, did not result in improvement of FFR or maxLCBI<sub>4mm</sub>. (ClinicalTrials.gov: NCT04141579).

EuroInterventionVol. 21(16)
Radboud University Nijmegen (NL), Medisch Spectrum Twente (NL), Radboud University Medical Center (NL), Maastricht University (NL), Albert Schweitzer Ziekenhuis (NL), Medisch Centrum Haaglanden (NL), Amphia Ziekenhuis (NL), Maasstad Ziekenhuis (NL), Assiut University (EG)
Good health and well-being
Openalex Percentile: Top 2%
Lipoproteins and Cardiovascular Health
10.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.